Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda variable 6-57 (IGLV6-57) is a variable region gene segment of the lambda light chain locus in human immunoglobulins. It encodes the variable (V) domain of lambda light chains, which combine with heavy chain variable domains to form the antigen-binding site of antibodies. V-region segments undergo recombination and hypermutation to provide antibody diversity. IGLV6-57-derived light chains are expressed in a minority of plasma cells, but are overrepresented in pathological monoclonal light chain production, especially in AL amyloidosis, where they are prone to misfolding and aggregation into amyloid fibrils. IGLV6-57 variable domains play a specific structural and physicochemical role in amyloid fibril formation, and their sequence features affect susceptibility to pathogenic aggregation[2][4]. IGLV6-57 is not a conventional therapeutic target like a receptor or enzyme, but its sequence and products are important as biomarkers in amyloidosis and for understanding antibody diversity[2][4][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda variable 6-57 (IGLV6-57).